Welcome to our dedicated page for Liminatus Pharma news (Ticker: LIMN), a resource for investors and traders seeking the latest updates and insights on Liminatus Pharma stock.
Liminatus Pharma, Inc. develops cancer immunotherapies, with news centered on its IBA101 program, a next-generation CD47-blocking monoclonal antibody for immuno-oncology. Company updates describe CD47 blockade, innate immune surveillance, macrophage-mediated tumor clearance, and clinical-development planning for use with established PD-1/PD-L1 checkpoint inhibitor approaches.
Recurring LIMN news also covers financing and capital-structure actions, shareholder voting and governance matters, Nasdaq-related disclosures, and regulatory communications tied to the company's public-company status and oncology development strategy.
Liminatus Pharma (Nasdaq: LIMN) has engaged Korea-based contract research organization Synex Consulting to support clinical development of IBC101, its autologous CD19xCD22 bivalent CAR-T cell therapy for relapsed or refractory B-cell malignancies. According to Liminatus, Synex will deliver clinical research services under a milestone-based program, with payments tied to key events such as patient enrollment, database lock and completion of the clinical study report.
IBC101 has received MFDS authorization in South Korea for a Phase 1/2a trial in relapsed or refractory diffuse large B-cell lymphoma, with Seoul St. Mary’s Hospital as lead site. The program broadens Liminatus’ immuno-oncology portfolio beyond its IBA101 anti-CD47 antibody, adding a clinical-stage hematologic malignancy pathway.
Liminatus Pharma (Nasdaq: LIMN) will implement a 1-for-50 reverse stock split of its common stock, effective at the close of trading on August 20, 2026, following prior stockholder approval at the 2026 Annual Meeting.
According to Liminatus, trading on a split-adjusted basis on the Nasdaq Capital Market will begin at market open on August 21, 2026 under the existing symbol LIMN, with a new CUSIP of 53271X 207. Every 50 issued and outstanding shares will be automatically combined into one share, with fractional shares rounded up to the nearest whole share and no cash in lieu. The reverse split will not change the par value or the number of authorized common or preferred shares, and stockholders’ proportional ownership and voting power will remain substantially unchanged, aside from nominal adjustments from fractional-share rounding.
Liminatus Pharma (Nasdaq: LIMN) announced that its common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026. The move enables LIMN shares to continue trading on Nasdaq under the existing ticker.
The Nasdaq Hearings Panel granted Liminatus an extension until September 3, 2026 to regain compliance with Nasdaq’s minimum bid price requirement. The company intends to take necessary actions within this period, and its stock will continue trading on the Nasdaq Capital Market, subject to ongoing compliance with the Panel’s decision and other Nasdaq continued listing standards.
Liminatus Pharma (Nasdaq: LIMN) amended its definitive merger agreement with InnocsAI, restructuring terms so the transaction can close before obtaining stockholder approval, now expected on July 2, 2026, subject to customary conditions.
InnocsAI equity holders will receive Liminatus common and non-voting convertible preferred stock at an issue price of $0.20 per common share, implying a transaction value of about $320 million, plus contingent value rights for 20% of future net proceeds from certain strategic transactions involving the acquired assets. Common stock issued at closing is limited to an estimated 19.99% of Liminatus’ outstanding common shares, with the balance in non-voting convertible preferred stock, convertible only after required stockholder approval. The combined company is expected to have an expanded oncology pipeline across cell therapy and immunotherapy, multiple preclinical candidates, proprietary IP, and a diversified platform targeting hematologic malignancies and solid tumors.
Liminatus Pharma (Nasdaq:LIMN) entered a warrant exercise agreement with existing accredited investors. Holders will immediately exercise 10,344,000 existing warrants for cash, providing $1.9 million in gross proceeds before fees.
In return, investors receive 20,688,000 new unregistered warrants at a $0.18 exercise price, exercisable only after required stockholder approval and expiring five years after that approval.
Liminatus Pharma (Nasdaq: LIMN) received a Nasdaq delisting notice after not regaining compliance with market value requirements. Nasdaq cited the $50,000,000 market value of listed securities and $15,000,000 market value of publicly held shares rules.
Unless Liminatus appeals by May 27, 2026, trading could be suspended May 29, 2026. The company plans to request a hearing, which would stay any suspension or delisting action pending the Panel decision.
Liminatus Pharma (LIMN) signed a definitive Merger Agreement to acquire InnocsAI via a subsidiary, aiming to expand its oncology cell therapy pipeline.
InnocsAI members will receive 1.6 billion Liminatus shares at $0.20 (about $320 million) plus contingent value rights to 20% of future net proceeds from certain strategic deals involving the acquired assets. The transaction adds CAR-T and antibody-based programs, including IBC101, a CD19xCD22 bivalent CAR-T authorized in Korea for a Phase 1/2a DLBCL study; INC101, a preclinical dual-antigen MSLNxCD276 CAR-T for solid tumors with a related armoured construct INC102; and a CS1 antibody platform intended to enable future trivalent CD19xCD22xCS1 CAR-T candidates. Closing is subject to shareholder and regulatory approvals and other customary conditions.
Liminatus (NASDAQ:LIMN) announced planned initiation of a Phase 1 clinical trial for IBA101, a next-generation CD47-blocking monoclonal antibody designed to engage innate immunity and complement PD-1/PD-L1 therapies.
The seamless study will begin with monotherapy dose escalation then add combination cohorts, initially focusing on lung cancer, and will include translational analyses to characterize immune activity. The company targets readiness after completing manufacturing, nonclinical, and regulatory preparations.
Liminatus Pharma (NASDAQ: LIMN) priced a best-efforts public offering of 13,813,000 common shares (or pre-funded warrants) and warrants to purchase 20,719,500 shares at a combined public offering price of $0.29 per share on February 17, 2026.
Gross proceeds are expected to be approximately $4.0 million, with potential additional proceeds of about $6.0 million if warrants are fully exercised; closing expected on or about February 18, 2026.
Liminatus Pharma (NASDAQ: LIMN) signed a Memorandum of Understanding with Capital Trust Group for a USD 30,000,000 equity financing via an earn-out mechanism to support R&D of its immuno-oncology programs. The investment is subject to due diligence, negotiation of definitive agreements, Nasdaq and U.S. securities compliance, and effectiveness of a registration statement for resale of the shares. Both parties target execution of definitive agreements in November 2025 and plan to discuss further strategic cooperation beginning mid-November, including potential digital bond financing programs.